The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CALC | -74.22% | -99.85% | -72.69% | -90% |
| S&P | +15.4% | +78.67% | +12.31% | +73% |
CalciMedica, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for life-threatening inflammatory diseases. The firm’s product candidate Auxora helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.
No news articles found for CalciMedica.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$11.00K | 26.7% |
| Market Cap | $42.98M | -9.8% |
| Market Cap / Employee | $3.07M | 0.0% |
| Employees | 14 | 0.0% |
| Net Income | -$7,804.00K | -38.9% |
| EBITDA | -$5,607.00K | 2.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.47M | -40.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.90M | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -148.18% | -63.4% |
| Return On Invested Capital | -75.22% | 7.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4,786.00K | -2.4% |
| Operating Free Cash Flow | -$4,778.00K | -2.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.22 | 1.79 | 2.05 | 7.04 | 104.61% |
| Price to Tangible Book Value | 4.22 | 1.79 | 2.05 | 7.04 | 104.61% |
| Enterprise Value to EBITDA | -4.30 | -1.69 | -2.20 | -7.35 | 21.02% |
| Return on Equity | -121.4% | -134.2% | -209.4% | -526.4% | 310.40% |
| Total Debt | $0.00K | $8.60M | $8.50M | $8.90M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
